HRP20140499T1 - Upotreba inhibitora histonske deacetilaze u lijeäśenju filadelfija-negativnih mijeloproliferativnih sindroma - Google Patents

Upotreba inhibitora histonske deacetilaze u lijeäśenju filadelfija-negativnih mijeloproliferativnih sindroma Download PDF

Info

Publication number
HRP20140499T1
HRP20140499T1 HRP20140499AT HRP20140499T HRP20140499T1 HR P20140499 T1 HRP20140499 T1 HR P20140499T1 HR P20140499A T HRP20140499A T HR P20140499AT HR P20140499 T HRP20140499 T HR P20140499T HR P20140499 T1 HRP20140499 T1 HR P20140499T1
Authority
HR
Croatia
Prior art keywords
methyl
hydroxycarbamoyl
naphthalen
carbamoyl
oxy
Prior art date
Application number
HRP20140499AT
Other languages
English (en)
Croatian (hr)
Inventor
Tiziano Oldoni
Paolo Mascagni
Alessandro Rambaldi
Tiziano Barbui
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of HRP20140499T1 publication Critical patent/HRP20140499T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20140499AT 2008-09-29 2009-09-21 Upotreba inhibitora histonske deacetilaze u lijeäśenju filadelfija-negativnih mijeloproliferativnih sindroma HRP20140499T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
US19328308P 2008-11-13 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (1)

Publication Number Publication Date
HRP20140499T1 true HRP20140499T1 (hr) 2014-07-04

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140499AT HRP20140499T1 (hr) 2008-09-29 2009-09-21 Upotreba inhibitora histonske deacetilaze u lijeäśenju filadelfija-negativnih mijeloproliferativnih sindroma

Country Status (17)

Country Link
US (4) US20110294892A1 (enExample)
EP (1) EP2344253B1 (enExample)
JP (1) JP2012504112A (enExample)
KR (3) KR20170124640A (enExample)
CN (1) CN102164638A (enExample)
BR (1) BRPI0913699A2 (enExample)
CA (1) CA2738081C (enExample)
CY (1) CY1115255T1 (enExample)
DK (1) DK2344253T3 (enExample)
ES (1) ES2478827T3 (enExample)
HR (1) HRP20140499T1 (enExample)
IT (1) IT1392908B1 (enExample)
PL (1) PL2344253T3 (enExample)
PT (1) PT2344253E (enExample)
SI (1) SI2344253T1 (enExample)
SM (1) SMT201400087B (enExample)
WO (1) WO2010034693A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
TW201821105A (zh) 2016-10-20 2018-06-16 美商弗瑪治療公司 使用ｈｄａｃ１１抑制劑之方法
EP3583155B1 (en) * 2017-02-20 2024-05-08 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US20080194681A1 (en) * 2004-12-09 2008-08-14 Kalypsys, Inc. Novel Inhibitors of Histone Deacetylase for the Treatment of Disease
EP1910342A1 (en) * 2005-07-29 2008-04-16 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
CN101426903A (zh) 2005-12-09 2009-05-06 麻省理工学院 基于细胞核形态鉴定并靶向肿瘤干细胞的方法
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Also Published As

Publication number Publication date
PT2344253E (pt) 2014-07-16
US9522127B2 (en) 2016-12-20
EP2344253A1 (en) 2011-07-20
JP2012504112A (ja) 2012-02-16
KR20170124640A (ko) 2017-11-10
CA2738081C (en) 2017-11-07
PL2344253T3 (pl) 2014-09-30
IT1392908B1 (it) 2012-04-02
CA2738081A1 (en) 2010-04-01
US20140039059A1 (en) 2014-02-06
CY1115255T1 (el) 2017-01-04
KR20160096721A (ko) 2016-08-16
BRPI0913699A2 (pt) 2017-06-13
DK2344253T3 (da) 2014-06-16
ITMI20081720A1 (it) 2010-03-30
EP2344253B1 (en) 2014-04-23
CN102164638A (zh) 2011-08-24
ES2478827T3 (es) 2014-07-23
US20110294892A1 (en) 2011-12-01
SI2344253T1 (sl) 2014-08-29
US20210128512A1 (en) 2021-05-06
US20170049740A1 (en) 2017-02-23
SMT201400087B (it) 2014-09-08
WO2010034693A1 (en) 2010-04-01
KR20110069075A (ko) 2011-06-22

Similar Documents

Publication Publication Date Title
ZA202502152B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
HRP20151443T1 (hr) Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
HRP20140499T1 (hr) Upotreba inhibitora histonske deacetilaze u lijeäśenju filadelfija-negativnih mijeloproliferativnih sindroma
AR070834A1 (es) Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
EA200601654A1 (ru) Ингибиторы интегразы вич
MX2009006285A (es) Inhibidores de transcriptasa inversa no nucleosidicos.
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
JP2006522813A5 (enExample)
EP2493312A4 (en) Solid pharmaceutical compositions containing an integrase inhibitor
NZ602478A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
EA201300892A1 (ru) Новые композиции для лечения муковисцидоза
NZ605469A (en) Nalbuphine-based formulations and uses thereof
TW200718689A (en) 2-Amino-quinazolin-5-ones
PH12012501965A1 (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
MY151835A (en) Kinase inhibitors and methods of use thereof
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
BRPI0912112B8 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
SI2985025T1 (en) A pharmaceutical combination
JP2012504112A5 (enExample)
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof